Alongside operational BRIDGE-building, Evotec is strategically considering challenges and best practices in transitioning from academic drug discovery to an investable proof of concept. Explore these strategic insights in our comprehensive White Paper series: ‘From academic concept to commercial reality: How to accelerate translational drug discovery’, where we openly share perspectives to stimulate dialogue among academic researchers, investors, and industry professionals. After presenting the Introduction, Chapter 1, and Chapter 2, today we introduce Chapter 3, titled 'Just Short of a Decathlon: A Day in the Life of a BRIDGE Expert in Residence' which concludes the series. You can download and read all chapters from our Science Pool - https://hubs.ly/Q02J4vnt0 #researchneverstops
Evotec BRIDGEs’ Post
More Relevant Posts
-
In Evotec's comprehensive White Paper series: ‘From academic concept to commercial reality: How to accelerate translational drug discovery’, we openly share perspectives to stimulate dialogue among academic researchers, investors, and industry professionals. Chapter 1: 'Finding a winning formula to lower barriers for academic researchers' explores the academic perspective on the challenges of translating new drug discovery concepts into robust proof of concept. Read it here - https://hubs.ly/Q02c6K6-0 #researchneverstops
To view or add a comment, sign in
-
-
Following our introductory publication, we now examine in detail the academic perspective on translating drug discovery innovations and associated challenges. Are there other challenges we need to address as a translational community?
In Evotec's comprehensive White Paper series: ‘From academic concept to commercial reality: How to accelerate translational drug discovery’, we openly share perspectives to stimulate dialogue among academic researchers, investors, and industry professionals. Chapter 1: 'Finding a winning formula to lower barriers for academic researchers' explores the academic perspective on the challenges of translating new drug discovery concepts into robust proof of concept. Read it here - https://hubs.ly/Q02c6K6-0 #researchneverstops
To view or add a comment, sign in
-
-
The journey goes on: please find Chapter 1 of White Paper series now online with the spotlight on the academic point of view on translational drug discovery. Enjoy reading - I am curious about your comments! #researchneverstops #BRIDGEs https://lnkd.in/eBWgzTdR
In Evotec's comprehensive White Paper series: ‘From academic concept to commercial reality: How to accelerate translational drug discovery’, we openly share perspectives to stimulate dialogue among academic researchers, investors, and industry professionals. Chapter 1: 'Finding a winning formula to lower barriers for academic researchers' explores the academic perspective on the challenges of translating new drug discovery concepts into robust proof of concept. Read it here - https://hubs.ly/Q02c6K6-0 #researchneverstops
To view or add a comment, sign in
-
-
Here we go with Chapter 1!
In Evotec's comprehensive White Paper series: ‘From academic concept to commercial reality: How to accelerate translational drug discovery’, we openly share perspectives to stimulate dialogue among academic researchers, investors, and industry professionals. Chapter 1: 'Finding a winning formula to lower barriers for academic researchers' explores the academic perspective on the challenges of translating new drug discovery concepts into robust proof of concept. Read it here - https://hubs.ly/Q02c6K6-0 #researchneverstops
To view or add a comment, sign in
-
-
Ela Plesnar holds a Ph.D. in biophysics and worked on groundbreaking projects for one of our clients, a leader in the emerging pharmatech industry. Discover the unique blend of skills and interdisciplinary expertise required to thrive in such projects. For more first-hand industry insights, read our blog article "ACCELERATING DRUG DISCOVERY: OUR SOFTWARE DEVELOPERS IN LIFE SCIENCE PROJECTS," featuring conversations with 🦦 Szymon Flakus, Ela Plesnar, Piotr Rożek, Karol Bubała, Łukasz Zawada, and Pawel Weber. Read the article: https://lnkd.in/dGqJnwj9 If you’re interested in these topics and will be in the UK on July 3rd, join our colleagues - Pawel Weber, Rafał Klimek, Dariusz Wiśniewski, and Karol Bubała - in Cambridge for a meetup titled "PRACTICAL ENGINEERING INSIGHTS FOR PHARMA AND BIO LEADERS." Attendance is free, but registration is required: https://lnkd.in/d7ShCGgz #DrugDiscovery #SoftwareDevelopers #LifeScience #SuccessFactors #Innovation
To view or add a comment, sign in
-
-
Scientific research is so exciting because "somewhere, something incredible is waiting to be known" (Carl Sagan). At Scientist.com we make your search for the 'incredible' easier, faster and more affordable. Check out the link below to our 2023 Year in Review and see what the future of scientific research looks like! https://lnkd.in/gZU4nEUi
To view or add a comment, sign in
-
Read the brief now: https://bit.ly/3WOmNT8 Launching a novel therapy with limited funding is already difficult, but it becomes even more daunting when the success of the product and the company are intertwined. Fortunately, there is a strategy that can increase your chances of success. In this advisory brief, Trinity Life Sciences will explore the “molecular optimizer” archetype — a strategy utilized by first-launch companies to focus on the optimization of an existing molecule as their first product. Additionally, we will delve into the advantages and disadvantages of employing this approach.
To view or add a comment, sign in
-
-
Involved in drug discovery? Watch our short video featuring Professor Stephen P. Wren and PhD Student Nathan Long in which they explain how their research group's work on a new and accessible novel synthetic compound library of building blocks for drug discovery is opening up new avenues for research. The Wren Group's recent paper, published in the SynOpen Thieme Journal, clarifies their work and explains more about how DrySyn and CondenSyn can improve conditions and reaction success as well as reduce environmental impact in your laboratory. Watch the full video here: https://buff.ly/3F3OiOQ #drugdiscoveryy #sustainablechemistry #realtimechem
To view or add a comment, sign in
-
-
Did you know that Bioz offers customizable badges for scientific products? Check out our page to explore how these badges can elevate your product visibility and credibility in the scientific community. Our badges provide instant access to valuable information, helping researchers make informed decisions faster. Join us in revolutionizing scientific discovery! 💫 #Bioz #BiozBadges #ScientificInnovation #B2BMarketing #ProductVisibility
Bioz Ratings For Life-Science Research
bioz.com
To view or add a comment, sign in
-
🚀 *Chelonia Applied Science: Pioneering the Future of Drug Discovery* "Science to Systems: Engineering Next-Gen Business Solutions" isn't just our motto at Chelonia Applied Science, it's our mission. We specialize in harnessing the power of data to revolutionize drug discovery. 🔬 *Transforming Data into Discovery* Our journey in drug discovery is fueled by advanced data analytics. By turning complex datasets into actionable insights, we're accelerating the development of breakthrough treatments. 💡 *Innovative Science, Real-World Impact* At Chelonia, we bridge the gap between theoretical science and practical application. Our innovative approaches are not just about discovering new drugs; they're about changing lives. 🤝 *Join Us on This Transformative Journey* Follow our story here on LinkedIn. Let's explore how data-driven science can lead to healthier futures. www.chelonia.swiss #CheloniaAppliedScience #DrugDiscovery #DataScience #InnovationInHealthcare
To view or add a comment, sign in
EVP, Head of Academic Partnerships at Evotec
1moProudly sharing the concluding chapter of our BRIDGEs White Papier series today - please enjoy a pre-Olympic summer read 😎